Entrada Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019
Net Income	65.63	-6.69	-94.62	-51.16	-26.52	Upgrade
Depreciation & Amortization	3.77	2.84	1.9	1.12	0.33	Upgrade
Loss (Gain) From Sale of Assets	-	-	-	0.07	0.02	Upgrade
Loss (Gain) From Sale of Investments	-10.02	-5.78	0.15	-	-	Upgrade
Stock-Based Compensation	17.92	13.11	9.9	2.53	0.33	Upgrade
Change in Accounts Receivable	2.2	-5.88	-	-	-	Upgrade
Change in Accounts Payable	0.99	-2.81	5.29	-0.72	0.63	Upgrade
Change in Unearned Revenue	-119.81	139.98	-	-	-	Upgrade
Change in Income Taxes	-3.36	4.02	-	-	-	Upgrade
Change in Other Net Operating Assets	1.12	1	-16.4	-2.71	-0.35	Upgrade
Operating Cash Flow	-41.56	139.8	-93.79	-50.86	-25.57	Upgrade
Capital Expenditures	-3.16	-5.61	-2.89	-4.58	-2.32	Upgrade
Investment in Securities	-24.64	-132.78	-145.76	-	-	Upgrade
Investing Cash Flow	-27.8	-138.4	-148.65	-4.58	-2.32	Upgrade
Issuance of Common Stock	102.96	21.04	0.48	191.63	0.25	Upgrade
Financing Cash Flow	102.96	21.04	0.48	307.46	50.09	Upgrade
Net Cash Flow	33.61	22.45	-241.96	252.02	22.2	Upgrade
Free Cash Flow	-44.72	134.19	-96.67	-55.44	-27.89	Upgrade
Free Cash Flow Margin	-21.21%	104.01%	-	-	-	Upgrade
Free Cash Flow Per Share	-1.15	4.06	-3.09	-8.85	-25.23	Upgrade
Cash Income Tax Paid	4.62	14.72	-	-	-	Upgrade
Levered Free Cash Flow	-73.29	149.04	-58.56	-36.26	-17.21	Upgrade
Unlevered Free Cash Flow	-73.29	149.04	-58.56	-36.26	-17.21	Upgrade
Change in Net Working Capital	121.2	-140.68	6.68	3.37	-1.13	Upgrade

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q